Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Eloxx Pharmaceuticals ( (ELOX) ) just unveiled an update.
Eloxx Pharmaceuticals has approved a significant stock option repricing, reducing the exercise price of its CEO’s options to a mere $0.0001, aligning with the closing stock price on October 16, 2024. This move, part of the 2018 Equity Incentive Plan, also accelerates the exercisability of these options, providing immediate full access regardless of previous vesting conditions. This strategic adjustment highlights the company’s effort to align executive incentives with shareholder interests.
See more data about ELOX stock on TipRanks’ Stock Analysis page.
